Cytosorbents Corp (CTSO) Financial Statements
Cytosorbents Corp (CTSO) reported trailing twelve-month revenue of $37.2M (up 3.1% year on year) and net income of -$18.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$9.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTSOCytosorbents CorpFollow CTSO — free
—
Price chart with a free account
- Market cap
- 16.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3 | 2.4 | 4.1 | 4.8 | 9.5 | 15.2 | 22.5 | 24.9 | 41.0 | 43.2 | 34.7 | 31.1 | 35.6 | 37.1 | 37.2 | |
| Gross profit | 1.0 | 0.5 | 2.0 | 2.6 | 5.6 | 9.6 | 15.0 | 17.6 | 30.0 | 32.1 | 20.7 | 22.0 | 24.9 | 26.5 | 26.6 | |
| Research & development | 2.5 | 1.7 | 2.4 | 3.9 | 4.1 | 3.2 | 7.7 | 12.1 | 8.8 | 16.4 | 15.1 | 15.7 | — | — | — | |
| Operating income | -3.5 | -4.7 | -6.9 | -9.3 | -11.5 | -9.8 | -15.6 | -19.0 | -10.4 | -22.7 | -31.5 | -31.9 | -16.5 | -14.7 | -12.9 | |
| Pre-tax income | -4.1 | -5.1 | -9.7 | -9.8 | -12.1 | -9.1 | -17.8 | -20.4 | -9.0 | -25.3 | -33.9 | -30.1 | -22.4 | -8.6 | -18.6 | |
| Income tax | -0.4 | -0.5 | -0.4 | -0.3 | -0.3 | -0.7 | -0.6 | -1.1 | -1.1 | -0.7 | -1.1 | -0.8 | -1.7 | -0.4 | -0.4 | |
| Net income | -3.7 | -4.7 | -9.3 | -9.5 | -11.8 | -8.5 | -17.2 | -19.3 | -7.8 | -24.6 | -32.8 | -29.2 | -20.7 | -8.2 | -18.2 | |
| Diluted EPS ($) | -0.03 | -0.75 | -1.29 | -0.38 | -0.46 | -0.32 | -0.56 | -0.60 | -0.20 | -11.40 | -15.00 | -13.00 | -7.60 | -2.60 | -5.80 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | — | 2.2 | 2.2 | 2.2 | 2.7 | 3.1 | — |
USD millions · SEC XBRL
Cytosorbents Corp — questions
- What is Cytosorbents Corp's revenue?
- $37.2M over the twelve months to 2026-06-30, up 3.1% year on year, from its 10-Q and 10-K filings.
- What is Cytosorbents Corp's net income?
- -$18.2M over the twelve months to 2026-06-30.
- What is Cytosorbents Corp's free cash flow?
- -$9.3M over the twelve months to 2026-06-30.
- What are Cytosorbents Corp's diluted earnings per share?
- $-5.80 over the twelve months to 2026-06-30.
Every figure on this page comes from Cytosorbents Corp's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.